Not looking at the business part just the medicine , Tollovir look like much better drug .. Hopefully phase 3 will start in USA very soon , and in the meantime let’s hope for EUAs in other countries ..
Very possible… it’s also quite possible VERU gets smacked down by the FDA as no other trial showed a 45% mortality in placebo group… This is unheard of
or, you could look at it as VERU's SP has tripled in one week on positive report. Therefore, if Todos can get to the stage that VERU got to, you might see an extremely quick appreciation in Todos's SP.... IFF.........
I think you really hit the nail on the head. What are we expecting Tollovid to do that Veru isn’t already? I just spent about 45 mins reading up on it.
“Sabizabulin 9mg is a novel once-a-day orally dosed small molecule that has both broad anti-inflammatory and anti-viral properties which may serve as a two-pronged approach to the treatment of COVID-19 virus infection and the subsequent debilitating inflammatory effects that can lead to ARDS and death.” And zero side effects.
So the good news is that unless something has been falsified in the trial. Covid just got knee capped. The stuff kicks COVID’s ass. And we should see it hit the market this year.
The bad news is. It has nothing to do with Todos. And Veru is at least a year ahead. And much better funded. So outside of a miracle, Todos is done.
Good news is that I think they are applying for EUA with 2 trials that together were under 250 people. So if Todos could pull off a 300 person trial ASAP. They might have a shot. I think a 300 person trial is affordable.
Other good news is Veru analysts are speculating at least a 225% increase in SP. So if I sell Todos now. I might make back a little of my 85% loss…
Looks like the better mouse trap from Veru is going to hit the market first. They won the race!
Market Data 
Markets 
AI
